Suppr超能文献

相似文献

1
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13045-50. doi: 10.1073/pnas.0806312105. Epub 2008 Aug 27.
3
Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.
J Lipid Res. 2013 Dec;54(12):3345-57. doi: 10.1194/jlr.M041129. Epub 2013 Oct 8.
4
Molecular basis for LDL receptor recognition by PCSK9.
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5. doi: 10.1073/pnas.0712064105. Epub 2008 Feb 4.
7
A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
Mol Genet Metab. 2010 Feb;99(2):149-56. doi: 10.1016/j.ymgme.2009.09.012. Epub 2009 Sep 27.
8
Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
PLoS One. 2015 Apr 23;10(4):e0125127. doi: 10.1371/journal.pone.0125127. eCollection 2015.
10
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
Biochem Biophys Res Commun. 2008 Oct 10;375(1):69-73. doi: 10.1016/j.bbrc.2008.07.106. Epub 2008 Jul 31.

引用本文的文献

2
Pathways and Molecular Mechanisms Governing LDL Receptor Regulation.
Circ Res. 2025 Apr 11;136(8):902-919. doi: 10.1161/CIRCRESAHA.124.323578. Epub 2025 Apr 10.
3
Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria.
Pflugers Arch. 2025 Jun;477(6):773-786. doi: 10.1007/s00424-025-03069-5. Epub 2025 Feb 18.
4
Lowering low-density lipoprotein cholesterol: from mechanisms to therapies.
Life Metab. 2022 May 20;1(1):25-38. doi: 10.1093/lifemeta/loac004. eCollection 2022 Aug.
5
Aerobic exercise alleviates statin-induced PCSK9 upregulation by increasing epoxyeicosatrienoic acid levels through the FoxO3a-Sirt6 axis.
J Sport Health Sci. 2024 Nov 6;14:101007. doi: 10.1016/j.jshs.2024.101007. eCollection 2025.
6
Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome.
Arch Rheumatol. 2024 Aug 24;39(3):375-383. doi: 10.46497/ArchRheumatol.2024.10462. eCollection 2024 Sep.
9
Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review).
Int J Mol Med. 2024 Jun;53(6). doi: 10.3892/ijmm.2024.5381. Epub 2024 May 17.

本文引用的文献

1
Molecular basis for LDL receptor recognition by PCSK9.
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5. doi: 10.1073/pnas.0712064105. Epub 2008 Feb 4.
2
The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain.
Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14604-9. doi: 10.1073/pnas.0703402104. Epub 2007 Sep 5.
3
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.
Biochem J. 2007 Sep 1;406(2):203-7. doi: 10.1042/BJ20070664.
4
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.
J Biol Chem. 2007 Jul 20;282(29):20799-803. doi: 10.1074/jbc.C700095200. Epub 2007 May 29.
5
The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.
Structure. 2007 May;15(5):545-52. doi: 10.1016/j.str.2007.04.004.
6
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
J Biol Chem. 2007 Jul 13;282(28):20502-12. doi: 10.1074/jbc.M701634200. Epub 2007 May 10.
8
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
Nat Struct Mol Biol. 2007 May;14(5):413-9. doi: 10.1038/nsmb1235. Epub 2007 Apr 15.
9
Molecular biology of PCSK9: its role in LDL metabolism.
Trends Biochem Sci. 2007 Feb;32(2):71-7. doi: 10.1016/j.tibs.2006.12.008. Epub 2007 Jan 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验